7-cyclopentyl-nn-dimethyl-2-5-piperazin-1-ylpyridin-2-ylamino-7h-pyrrolo23-dpyrimidine-6-carboxamide-succinate-98

1374639-75-4 7-Cyclopentyl-N,N-dimethyl-2-((5-(piperazin-1-yl)pyridin-2-yl)amino)-7H-pyrrolo[2,3-d]pyrimidine-6-carboxamide succinate, 98%

Synonym(s):

7-cyclopentyl-N,N-dimethyl-2-((5-(piperazin-1-yl)pyridin-2-yl)amino)-7H-pyrrolo[2,3-d]pyrimidine-6-carboxamide succinate,Ribociclib Succinate

Purity : > 98 %

CAS Number: 1374639-75-4

Molecular Weight: 552.63

Emperical Formula

EC Number:

MDL Number: MFCD28167746

SKU	Pack Size	Availability	Price	Quantity
Ribociclib Succinate	1 / Grams	Available to ship on 06-08-2024 (Three weeks from Order Confirmation)	₹ 10,000	- +

Request a Bulk Order

Product Number

CLSOP1003

Purity / Analysis Method

> > 98 %

Molecular Formula / Molecular Weight

552.63

Physical State (20 deg.C)

Solid

Packaging and Container

CAS RN

Reaxys Registry Number

PubChem Substance ID

SDBS (AIST Spectral DB)

Merck Index (14)

MDL Number

MFCD28167746

Specifications

Appearance

Purity(HPLC)

Purity(Neutralization titration)

Properties (reference)

Melting Point

Solubility in water

Solubility (soluble in)

GHS

Signal Word

GHS06,GHS08,GHS09

Hazard Statements

Precautionary Statements

Related Laws:

RTECS#

Transport Information:

Ribociclib is a selective cyclin-dependent kinase inhibitor, a class of drugs that help slow the progression of cancer by inhibiting two proteins called cyclin-dependent kinase 4 and 6 (CDK4/6). These proteins, when over-activated, can enable cancer cells to grow and divide too quickly. Targeting CDK4/6 with enhanced precision may play a role in ensuring that cancer cells do not continue to replicate uncontrollably. Ribociclib was approved by the U.S. FDA in March, 2017 as Kisqali.